Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron — Clinical Trial Site

24 Registered trials

4 Currently recruiting

Organisation

Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Location

Barcelona, Spain

Identifier

ORG-100026497

Address

Passeig Vall D Hebron 119-129, 08035, Spain

Departments

Departamento de Oncologia- VHIO
Hematology
Intensive Care Unit
Materno Infantil
Medical Oncology
Medical Oncology Department
N/A
NEPHROLOGY
Oncología
Oncology
Oncology Department
Ped Oncology
Rheumatology
Servicio de Hepatología
Servicio de oncologia medica
site 004_Centro de Salud Internacional y Enfermedades Transmisibles Drassanas Sant Oleguer, 17

Clinical trials at this site (24)

Search interface

Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised

2023-503480-42-00 Hospital-acquired pneumonia 10
Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant re… Recruiting

2022-502624-44-00 kidney transplantation 5 2024-12-10
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Study of the efficacy of intratumoral injections of L19IL2 + L19TNF followed by surgery to prevent or retard appearance of new metastases Recruiting

2023-507119-36-00 Malignant melanoma of the skin in patients with locally 5 2022-05-09
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting

2023-504880-18-00 Neuroblastoma (NBL) 9 2018-04-18
IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS Ended

2023-506478-11-01 chronic kidney disease 9 2025-08-28
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines… Ended

2022-502228-34-00 ER +/HER2- Advanced or Metastatic Breast Cancer 9 2023-12-27
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety tolerability, pharmacokinetics… Ended

2023-510061-10-00 Clear cell renal cell carcinoma (ccRCC, first-, second- 3 2023-01-09
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Advanced Colorectal Cancer with KRAS G12C Mutation 5 2021-11-30
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic… Ended

2023-506257-37-00 Active Psoriatic Arthritis 5 2021-10-29
Study on an Investigational Yellow Fever Vaccine Compared with Stamaril in Adults in Europe and Asia Ended

2022-502047-35-00 Yellow fever 4 2021-10-07
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Solid tumors 4 2021-03-15
A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended

2023-509405-77-00 Colorectal cancer (BRAF V600E-mutant mCRC) 5 2021-02-16
Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera… Ended

2022-501973-37-00 Endometrial cancer 5 2020-01-30
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Lymphoma of B-cell origin 7 2018-05-16
An open-label extension study of pertuzumab administered on its own or in combination with other anti-cancer therapies in patients previousl… Ended

2023-505102-42-00 Solid Malignant Tumors 5 2014-12-18
A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-X… Ended

2022-501952-27-00 Hospital-acquired bacterial pneumonia (HABP), including 5 2024-04-19
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended

2023-503739-16-00 Relapsed or refractory solid tumors or non-Hodgkin lymp 1 2023-12-20
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa… Ended

2023-508489-14-00 Solid Tumors 4 2023-09-18
APTIVATE Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with… Ended

2023-503244-14-00 Relapsed or Refractory Acute Myeloid Leukemia (AML) 7 2023-08-11
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) Ended

2024-511116-25-00 Multiple Myeloma 1 2022-12-13
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications Ended

2023-510511-19-00 Advanced Solid Tumors 7 2021-11-08
Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Su… Ended

2022-501971-24-00 Adjuvant treatment of HCC 5 2019-05-20
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended

2023-508757-75-00 Stage IV Non-Small Cell Lung Cancer (NSCLC) 5 2017-09-18